Insider Transactions in Q4 2025 at Pacira Bio Sciences, Inc. (PCRX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
Shawn Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,104
-13.93%
|
$227,600
$25.14 P/Share
|
|
Dec 10
2025
|
Shawn Cross Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,104
+12.23%
|
$145,664
$16.45 P/Share
|
|
Dec 09
2025
|
Shawn Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,896
-22.03%
|
$397,400
$25.03 P/Share
|
|
Dec 09
2025
|
Shawn Cross Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,896
+18.06%
|
$254,336
$16.45 P/Share
|
|
Nov 17
2025
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,960
-2.17%
|
$95,040
$24.09 P/Share
|
|
Nov 10
2025
|
Shawn Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,060
-17.65%
|
$265,320
$22.09 P/Share
|
|
Oct 31
2025
|
Shawn Cross Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,690
-8.92%
|
$140,490
$21.38 P/Share
|